...
机译:Toremifene而不是Tamoxifen,可能是中国CYP2D6 * 10T / T基因型乳腺癌患者的佐剂内分泌治疗更好的选择
Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer;
Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer;
Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer;
Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer;
Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer;
Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer;
Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer;
Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer;
Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer;
Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer;
Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer;
Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer;
Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer;
breast cancer; TAM; TOR; CYP2D6; SNP;
机译:Toremifene而不是Tamoxifen,可能是中国CYP2D6 * 10T / T基因型乳腺癌患者的佐剂内分泌治疗更好的选择
机译:Re:CYP2D6基因型和他莫昔芬反应对绝经后内分泌反应性乳腺癌妇女的影响:乳腺癌国际组1-98试验和Re:CYP2D6和UGT2B7基因型与他莫昔芬治疗的乳腺癌患者的复发风险
机译:中国汉族人群乳腺癌患者佐剂内分泌治疗CYP2D6多态性与三莫莫芬疗效的关系
机译:佐剂中子治疗复杂治疗局部晚期乳腺癌患者
机译:辅助性他莫昔芬治疗妇女饮食中与乳腺癌风险生物标志物的关联。
机译:CYP2D6 * 10(c.100C T)多态性与他莫昔芬辅助内分泌治疗后中国人群乳腺癌临床结局的关系
机译:Toremifene(而不是Tamoxifen)可能是中国CYP2D6 * 10T / T基因型乳腺癌患者的佐剂内分泌治疗更好的选择